Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to identifying, developing, and commercializing life-changing medicines for people with serious diseases, often with limited or no therapeutic options. The company's mission is to innovate to transform the lives of patients and their families. Headquartered in Dublin, Ireland, Jazz Pharmaceuticals focuses on addressing significant unmet medical needs worldwide.

The company's diverse portfolio of marketed medicines primarily targets neuroscience and oncology. Key neuroscience products include Xywav and Xyrem for narcolepsy and idiopathic hypersomnia, and Epidiolex for severe forms of epilepsy such as Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. In oncology, Jazz Pharmaceuticals offers Zepzelca for metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, Vyxeos for acute myeloid leukemia, and Ziihera for HER2-positive biliary tract cancer. The company also has Modeyso (dordaviprone) in its portfolio for H3 K27M-mutant diffuse glioma.

Under the leadership of President and CEO Renée Galá, Jazz Pharmaceuticals continues to advance its pipeline and market presence. Recent notable developments include the FDA's acceptance with Priority Review for Ziihera (zanidatamab-hrii) combinations as a first-line therapy for HER2-positive unresectable locally advanced or metastatic gastric, GEJ, or gastroesophageal adenocarcinoma, with a PDUFA target action date of August 25, 2026. The company reported record total revenue of $4.3 billion in 2025, driven by strong performance from key products like Xywav and Epidiolex, reinforcing its position as a specialist innovator in areas of high unmet medical need.